{"nctId":"NCT04145531","briefTitle":"An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)","startDateStruct":{"date":"2019-12-27","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Leukemia"],"count":229,"armGroups":[{"label":"JZP-458","type":"EXPERIMENTAL","interventionNames":["Drug: IM JZP-458","Drug: IV JZP-458"]}],"interventions":[{"name":"IM JZP-458","otherNames":[]},{"name":"IV JZP-458","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Pediatric and adult patients with a diagnosis of ALL or LBL.\n2. Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation.\n3. Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan.\n4. Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase.\n\nExclusion Criteria:\n\n1. Have previously received asparaginase Erwinia chrysanthemi or JZP-458.\n2. Have relapsed ALL or LBL.\n3. Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458.\n4. Have a history of ≥ Grade 3 pancreatitis.\n5. Prior history of asparaginase-associated ≥ Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate During the First Course of JZP-458 Administration","description":"The response rate was defined as the number (proportion) of patients with the last 72-hour nadir serum asparaginase activity (NSAA) level ≥ 0.1 IU/mL during the first course of IM JZP-458. Blood samples were collected for serum asparaginase activity level determination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered related to study drug. AEs were classified by the Investigator using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Last 48-hour NSAA Level ≥ 0.1 IU/mL During The First Course (6 Doses) of JZP-458 Administration","description":"Blood samples were collected for serum asparaginase activity level determination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Last NSAA Levels ≥ 0.4 IU/mL During The First Course (6 Doses) of JZP-458 Administration","description":"Blood samples were collected for serum asparaginase activity level determination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Serum Asparaginase Activity Levels in First Course of JZP-458 Administration","description":"Serum asparaginase levels serve as a surrogate marker for asparagine depletion. Mean serum asparaginase activity levels in Course 1 are reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.88","spread":null},{"groupId":"OG002","value":"0.66","spread":null},{"groupId":"OG003","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.33","spread":null},{"groupId":"OG002","value":"0.47","spread":null},{"groupId":"OG003","value":"0.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Are Anti-drug Antibody Positive or Negative Against JZP-458","description":"Blood samples were collected for immunogenicity analysis. Anti-drug antibody positive (ADA+) participants were those with a positive result on the first test and also a positive result on the confirmatory test. Anti-drug antibody negative (ADA-) participants had a negative result on the first test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":33},"commonTop":["Anaemia","Vomiting","Platelet count decreased","Neutrophil count decreased","Nausea"]}}}